CSL Limited Annual Report 2021/22 60 Joy Linton BComm; F. Fin; GAICD Chief Financial Officer Joy was appointed Chief Financial Officer in March 2021. Prior to joining CSL, Joy was chief financial officer and executive director at Bupa, a global health insurance company based in the UK, and earlier served as the general manager of health services for Bupa UK. Joy has over 30 years’ experience in branded consumer businesses across insurance, healthcare and fast-moving consumer goods as a global and strategic chief financial officer. Paul McKenzie PhD (Chemical Engineering) Chief Operating Officer Paul was appointed Chief Operating Officer in June 2019 and leads CSL’s global end-to-end operations organisation and its accompanying strategy. He has responsibility for manufacturing, quality, engineering, supply chain, procurement and environment, health and safety, as well as CSL Plasma and its network of collection centres in the US, China and Europe. Paul also has responsibility for CSL Seqirus. Prior to joining CSL, Paul served as executive vice president of Pharmaceutical Operations and Technology at Biogen. With more than 25 years of experience, Paul held various senior roles in research and development and manufacturing for Johnson & Johnson, Bristol-Myers Squibb and Merck & Co. Paul holds a Bachelor of Science degree in chemical engineering from the University of Pennsylvania and a PhD in chemical engineering from Carnegie Mellon University. He was elected to the National Academy of Engineering in 2020. Bill Mezzanotte MD, MPH Executive Vice President, Head Research & Development and Chief Medical Officer As the Head of Research & Development (R&D) and Chief Medical Officer, Bill is responsible for developing and executing CSL’s R&D strategy and portfolio, creating the pipeline and R&D capabilities that will help the CSL Behring and CSL Seqirus businesses grow in the decades ahead. These R&D capabilities include identifying and developing all scientific platforms, skills and expertise necessary for success in rare and serious diseases and vaccines. Bill, who has been leading R&D since October 2018, initially joined CSL as head of clinical development in 2017. Prior to CSL, Bill was senior vice president and therapeutic area head for the respiratory unit for Boehringer Ingelheim and spent 16 years with AstraZeneca in research and development, assuming roles of increasing leadership and management responsibility across multiple therapeutic areas. Bill obtained his MD at the University of Pennsylvania and a Master of Public Health degree from Johns Hopkins University. He is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine. Since 2020, Bill has served as a member of the Board of Directors of the Philadelphia-based University City Science Center and in 2021 he joined the Board of Directors for BELLUS Health. Elizabeth Walker BA, MS (Organisational Development and Leadership) Executive Vice President, Chief Human Resources Officer Elizabeth Walker leads Global Human Resources for the CSL Group of Companies and its people and culture strategy, supporting more than 30,000 employees around the world. Elizabeth joined CSL in 2016 and was appointed Chief Human Resources Officer in December 2017. Previously, she held a variety of HR leadership positions at Campbell Soup Company, most recently as Vice President of Global Talent Management. With a career spanning more than 30 years, she has extensive human resources and management consulting expertise and a distinguished record of results in growth businesses and M&A environments and within a diverse set of industries, including healthcare, financial services and consumer products. Elizabeth holds a Master of Science degree in organization development and leadership from St. Joseph’s University and a Bachelor of Arts degree from Carnegie Mellon University Allan Wills, former Executive Vice President, Strategy and Business Development, resigned from CSL effective 30 November 2021. 10 Governance
RkJQdWJsaXNoZXIy MjE2NDg3